

Nr. crt.	Cod protocol	Numar EudraCT	Medicament de investigatie clinica testat	Medicament de investigatie clinica comparator	Placebo	Aria terapeutică	Sponsor	International / national	Denumirea studiului (s-a pastrat denumirea originala - in limba engleza)	Faza	Nr. estimat de pacienti pentru Romania	Data autorizarii studiului clinic de catre ANMDM	Data opiniei CNBMDM	Data inceperii studiului	Inchidere studiu la nivel global/ Romania
1	B7931028	2018-004175-12	PF-06700841	Nu	Da	Colagenoze	Pfizer Inc., SUA	multicentric	A Phase 2B, Double-blind, Randomized, Placebo-controlled, Multicenter, Dose-ranging Study to Evaluate the Efficacy and Safety Profile of PF-06700841 in Participants with Active Systemic Lupus Erythematosus (SLE)	II	13	8/1/2019			
2	SPR994-301	2018-003671-35	TBPM-PI-HBr	INVANZ (Ertapenem)	Da	Infectie urinare	Spero Therapeutics, Inc., SUA	multicentric	A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients with Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)	III	70	8/6/2019	6/13/2019		
3	AB12006 RESPINS	2013-000490-79	masitinib mesylate (AB1010)	Nu	Da	Afecțiuni oncologice	AB Science	multicentric	A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients with metastatic colorectal cancer	III	200	06.08.2019 Respins			
4	APD334-301	2018-003985-15	Etrasimod (APD334)	Nu	Da	Boli ale sistemului digestiv	Arena Pharmaceuticals Inc., SUA	multicentric	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis	III	12	8/20/2019			
5	POISE-3 REPINS	2018-000539-29	acid tranexamic				Hamilton Health Sciences Corporation, University Medical Center Utrecht, Olanda	multicentric	PeriOperative ISchemic Evaluation-3 Trial (POISE-3) Trial	III		8/20/2019			
6	REMAP-CAP	2015-002340-14	Levofloxacin	Multiple terapii	Nu	Boli pulmonare/ infectioase	Medical Center Utrecht, Olanda	unicentric	Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)	IV	200	8/30/2019	3/11/2019		
7	91501	2015-005781-39	FEIBA	Nu	Nu	Boli hematologice	Baxalta Innovations GmbH, Austria	multicentric	A Phase 3b/4, Prospective, Multicenter, Open-label, Randomized, Crossover Study of Tolerability and Safety of FEIBA Reconstituted in Regular or 50% Reduced Volume and of Faster Infusion Rates in Patients with Hemophilia A or B with Inhibitors	III/IV	2	8/30/2019			
8	CF101-301PS	2017-000214-27	piclidenoson (CF101)	Otezla 30 mg capsule (Apremilast)	Da	Boli dermatologice	Can-Fite BioPharma, Ltd., Israel	multicentric	A Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study of the efficacy and Safety of Daily Piclidenoson (CF101) Administered Orally in Patients with Moderate-to-Severe Plaque Psoriasis	III	65	8/30/2019			
9	GLPG1205-CL-220	2017-004302-18	GLPG1205	Nu	Da	Boli pulmonare	Galapagos NV, Belgia	multicentric	A Phase II randomized, double-blind, placebo-controlled, 26-week study to evaluate the efficacy, safety and tolerability of GLPG1205 in subjects with idiopathic pulmonary fibrosis	II	23	8/30/2019	11/22/2018		
10	ACP-103-047	2017-004439-36	pimavanserin (ACP-103)	Nu	Nu	Boli neuro-psihiatrice	ACADIA Pharmaceuticals Inc., SUA	multicentric	A 52-Week Open-Label Extension Study of Pimavanserin in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease	III	23	8/30/2019	10/24/2018		
11	ACP-103-046	2017-003536-36	pimavanserin (ACP-103)	Nu	Nu	Boli neuro-psihiatrice	ACADIA Pharmaceuticals Inc., SUA	multicentric	A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease	III	35	8/30/2019	10/24/2018		
12	RLM-MD-02	2017-002177-20	relamorelin (RM-131)	Nu	Da	Diabet-complicatii	Allergan Ltd., UK	multicentric	A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis	III	12	8/30/2019			
13	RLM-MD-04	2017-002144-33	relamorelin (RM-131)	Nu	Da	Diabet-complicatii	Allergan Ltd., UK	multicentric	A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis	III	6	8/30/2019			
14	RLM-MD-03	2017-002143-15	relamorelin (RM-131)	Nu	Da	Diabet-complicatii	Allergan Ltd., UK	multicentric	A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis	III	10	8/30/2019			
15	IM011023	2017-001976-48	BMS-986165	Nu	Da	Boli ale sistemului digestiv	Bristol-Myers Squibb International Corporation, Belgia	multicentric	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Crohn's Disease	II	12	8/30/2019	2/28/2019		
16	0173	2018-001272-37	TD-1473	Nu	Da	Boli ale sistemului digestiv	Theravance Biopharma Ireland Limited, Irlanda	multicentric	A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy with 2 Doses of TD-1473 in Subjects with Moderately-to-Severely Active Crohn's Disease	II	9	8/30/2019	1/17/2019		